About

About Clarametyx Biosciences Clarametyx Biosciences is combating the formidable challenge of chronic respiratory diseases through an innovative technology platform targeting bacterial biofilms. The Columbus, Ohio-based company is building a pipeline of immune-enabling medicines, including CMTX-101, which completed a positive Phase 2 study in cystic fibrosis patients in early 2026, and plans to pursue additional mid-stage studies in other chronic respiratory diseases including bronchiectasis. The company’s second program, CMTX-301, is in early development to evaluate the technology in a preventive approach. Clarametyx Biosciences is combating the formidable challenge of chronic, recalcitrant respiratory disease decline through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response and antibiotic intervention. The Columbus, Ohio-based company is building a pipeline of immune-enabling therapies and vaccines, including CMTX-101, which is in a Phase 2a study for infections associated with cystic fibrosis, and CMTX-301, an anti-biofilm vaccine in early development.